Literature DB >> 25719402

Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity.

Qiuqiong Cheng1, Yuka Inaba, Peipei Lu, Meishu Xu, Jinhan He, Yueshui Zhao, Grace L Guo, Ramalinga Kuruba, Rona de la Vega, Rhobert W Evans, Song Li, Wen Xie.   

Abstract

The nuclear receptor farnesoid X receptor (FXR) (nuclear receptor subfamily 1, group H, member 4, or NR1H4) is highly expressed in the liver and intestine. Previous reports have suggested beneficial functions of FXR in the homeostasis of bile acids, lipids, and glucose, as well as in promoting liver regeneration and inhibiting carcinogenesis. To investigate the effect of chronic FXR activation in vivo, we generated transgenic mice that conditionally and tissue specifically express the activated form of FXR in the liver and intestine. Unexpectedly, the transgenic mice showed several intriguing phenotypes, including partial neonatal lethality, growth retardation, and spontaneous liver toxicity. The transgenic mice also displayed heightened sensitivity to a high-cholesterol diet-induced hepatotoxicity but resistance to the gallstone formation. The phenotypes were transgene specific, because they were abolished upon treatment with doxycycline to silence the transgene expression. The perinatal toxicity, which can be rescued by a maternal vitamin supplement, may have resulted from vitamin deficiency due to low biliary bile acid output as a consequence of inhibition of bile acid formation. Our results also suggested that the fibroblast growth factor-inducible immediate-early response protein 14 (Fn14), a member of the proinflammatory TNF family, is a FXR-responsive gene. However, the contribution of Fn14 induction in the perinatal toxic phenotype of the transgenic mice remains to be defined. Because FXR is being explored as a therapeutic target, our results suggested that a chronic activation of this nuclear receptor may have an unintended side effect especially during the perinatal stage.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25719402      PMCID: PMC4399273          DOI: 10.1210/me.2014-1337

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  44 in total

1.  Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.

Authors:  Chiara Degirolamo; Salvatore Modica; Michele Vacca; Giuseppe Di Tullio; Annalisa Morgano; Andria D'Orazio; Kristina Kannisto; Paolo Parini; Antonio Moschetta
Journal:  Hepatology       Date:  2014-10-30       Impact factor: 17.425

2.  Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity.

Authors:  Florence Ying Lee; Thomas Quad de Aguiar Vallim; Hansook Kim Chong; Yanqiao Zhang; Yaping Liu; Stacey A Jones; Timothy F Osborne; Peter A Edwards
Journal:  Mol Endocrinol       Date:  2010-06-23

3.  Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia.

Authors:  Yanqiao Zhang; Liya Yin; Jody Anderson; Huiyan Ma; Frank J Gonzalez; Timothy M Willson; Peter A Edwards
Journal:  J Biol Chem       Date:  2009-12-07       Impact factor: 5.157

4.  Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription.

Authors:  Wei-Dong Chen; Yan-Dong Wang; Lisheng Zhang; Steven Shiah; Meihua Wang; Fan Yang; Donna Yu; Barry M Forman; Wendong Huang
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

5.  Identification of a nuclear receptor for bile acids.

Authors:  M Makishima; A Y Okamoto; J J Repa; H Tu; R M Learned; A Luk; M V Hull; K D Lustig; D J Mangelsdorf; B Shan
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

6.  Disruption of cholesterol 7alpha-hydroxylase gene in mice. I. Postnatal lethality reversed by bile acid and vitamin supplementation.

Authors:  S Ishibashi; M Schwarz; P K Frykman; J Herz; D W Russell
Journal:  J Biol Chem       Date:  1996-07-26       Impact factor: 5.157

7.  Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.

Authors:  Raffaella M Gadaleta; Karel J van Erpecum; Bas Oldenburg; Ellen C L Willemsen; Willem Renooij; Stefania Murzilli; Leo W J Klomp; Peter D Siersema; Marguerite E I Schipper; Silvio Danese; Giuseppe Penna; Gilles Laverny; Luciano Adorini; Antonio Moschetta; Saskia W C van Mil
Journal:  Gut       Date:  2011-01-17       Impact factor: 23.059

Review 8.  A role of the bile salt receptor FXR in atherosclerosis.

Authors:  Jurre Hageman; Hilde Herrema; Albert K Groen; Folkert Kuipers
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-08       Impact factor: 8.311

Review 9.  Bile acids: trying to understand their chemistry and biology with the hope of helping patients.

Authors:  Alan F Hofmann
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

10.  A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis.

Authors:  Jung Hoon Lee; Taira Wada; Maria Febbraio; Jinhan He; Tsutomu Matsubara; Min Jae Lee; Frank J Gonzalez; Wen Xie
Journal:  Gastroenterology       Date:  2010-03-17       Impact factor: 22.682

View more
  6 in total

1.  Chronic activation of FXR-induced liver growth with tissue-specific targeting Cyclin D1.

Authors:  Weibin Wu; Qing Wu; Xinmei Liu
Journal:  Cell Cycle       Date:  2019-06-25       Impact factor: 4.534

Review 2.  An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.

Authors:  Frank J Gonzalez; Changtao Jiang; Andrew D Patterson
Journal:  Gastroenterology       Date:  2016-09-14       Impact factor: 22.682

3.  Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.

Authors:  Brett M McGettigan; Rachel H McMahan; Yuhuan Luo; Xiaoxin X Wang; David J Orlicky; Cara Porsche; Moshe Levi; Hugo R Rosen
Journal:  J Biol Chem       Date:  2016-09-07       Impact factor: 5.157

4.  Fibroblast Growth Factor 15-Dependent and Bile Acid-Independent Promotion of Liver Regeneration in Mice.

Authors:  Bo Kong; Runbin Sun; Mingxing Huang; Monica D Chow; Xiao-Bo Zhong; Wen Xie; Yi-Horng Lee; Grace L Guo
Journal:  Hepatology       Date:  2018-10-08       Impact factor: 17.425

5.  Liver Cholesterol Overload Aggravates Obstructive Cholestasis by Inducing Oxidative Stress and Premature Death in Mice.

Authors:  Natalia Nuño-Lámbarri; Mayra Domínguez-Pérez; Anna Baulies-Domenech; Maria J Monte; Jose J G Marin; Patricia Rosales-Cruz; Verónica Souza; Roxana U Miranda; Leticia Bucio; Eduardo E Montalvo-Jave; María Concepción Gutiérrez-Ruiz; Carmen García-Ruiz; José C Fernández-Checa; Luis Enrique Gomez-Quiroz
Journal:  Oxid Med Cell Longev       Date:  2016-08-21       Impact factor: 6.543

6.  Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.

Authors:  Prue M Pereira-Fantini; Susan Lapthorne; Cormac G M Gahan; Susan A Joyce; Jenny Charles; Peter J Fuller; Julie E Bines
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-03-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.